PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9750490

[Prostatic mass screening program and its technology].

H Watanabe·S Nakagawa
View original source ↗Export metadata ↓

Abstract

In 1975, we originally developed a mass screening program for prostatic cancer (PC) using transrectal sonography (TRS). In the primary study, males more than the age of 55 years were examined by TRS and subjects with any pathological findings on the sonogram were referred to secondary examination. In the secondary examination, biopsy of prostate was carried out under ultrasonic guidance. Since 1984, we included digital rectal examination (DRE) in the primary study. We further studied prostate specific antigen (PSA) in 1987. From 1995, mass screening program for PC using PSA has been performed. In the primary study, subjects were examined by PSA and the cut-off values were set at 4 and 10 ng/ml. Subjects whose PSA level ranged from 4.1 to 10.0 ng/ml (gray zone) were examined by DRE, TRS and PSA density (more than 0.15) in the secondary study, then the suspected subjects of PC underwent 6 sextant biopsies under interventional ultrasound. Subjects whose PSA level was more than 10.1 ng/ml were biopsied directly. According to a survey by the Foundation for prostate Research, the similar field screening has been performed in Japan by 32 groups for a total of 97,066 subjects, detecting 817 (0.8%) cancer cases up to 1995 and 431 of them (53%) were in the early stage. Prostatic screening is thus being recognized as an important part of preventive oncology at a national level in Japan.

Explore related subjects

HumansMaleMass ScreeningProstatic NeoplasmsEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Watanabe, S Nakagawa. 1998. [Prostatic mass screening program and its technology].. https://pubmed.ncbi.nlm.nih.gov/9750490/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2027

Global Genomic Surveillance.

Global genomic surveillance has emerged as a foundational pillar of public health in the twenty-first century, enabling real-time tracking of pathogen evolution and informing outbreak response. This chapter examines the strategic architecture of global genomic surveillance, focusing on its application to arboviruses such as chikungunya virus (CHIKV). It explores the integration of genomic data with epidemiological, clinical, and environmental information within a One Health framework, while addressing critical challenges in governance, equity, and interoperability. The discussion covers the entire genomic surveillance workflow, from sample collection and sequencing to bioinformatic analysis and phylogenetic inference, and highlights the transformative role of artificial intelligence (AI) in predictive surveillance. By analyzing global initiatives, operational barriers, and emerging technologies, this chapter underscores the necessity of sustainable, equitable, and interoperable genomic systems to proactively address current and future infectious disease threats.

Humans↗
PubMed2027

Systematic Dissection of Key Driver Perturbation Signatures in Single Cells via ECCITE-seq.

CRISPR screens, such as expanded CRISPR-compatible cellular indexing of transcriptomes and epitopes by sequencing (ECCITE-seq), enable the simultaneous measurement of transcriptomes, gRNA identity, and cell-surface protein expression at single-cell resolution to systematically interrogate gene function. This platform provides a powerful and scalable experimental approach for validating disease-associated regulators identified by large-scale association studies and other computational methods, including network-based analyses of multi-omics data. Here, as an example application, we describe an ECCITE-seq framework to characterize the transcriptomic consequences of perturbing multiple neuronal key driver genes associated with Alzheimer's disease (AD) in human-induced pluripotent stem cell (hiPSC)-derived neurons. More broadly, by integrating customized pooled gRNA libraries with different CRISPR effectors across multiple cell types, this approach allows for the assessment of the regulatory impact of candidate genes implicated in development and disease processes.

Humans↗
PubMed2027

Identification of Genome-Wide Chromatin Structural Aberration in Cancer by Hi-C Analysis.

Aberrant three-dimensional genome organization is a hallmark of cancer, often driving oncogene activation through mechanisms such as enhancer hijacking. High-throughput chromosome conformation capture (Hi-C) maps these interactions on a genome-wide scale. Unlike earlier dilution-based methods, in situ Hi-C performs proximity ligation within intact nuclei, minimizing random ligation noise and enabling fine-scale structure detection. This chapter describes an optimized in situ Hi-C protocol tailored for cancer cell lines using MboI digestion and biotin-mediated pull-down to generate high-complexity libraries. We further outline a computational workflow that extends beyond standard topological mapping of compartments and topologically associating domains to identify cancer-specific aberrations. Specifically, we focus on detecting chromosomal rearrangements (structural variants) and characterizing the distinct circular topology of extrachromosomal DNA. This integrated experimental and analytical framework provides the necessary tools to dissect the spatial dysregulation underlying tumor evolution.

Humans↗